Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) Activity (TRACer)

10. november 2026 oppdatert av: Randall F Holcombe, University of Vermont Medical Center

This study will examine how low doses of ethacrynic acid affect substances in the blood involved in protecting cells from damage. These substances include glutathione and an enzyme called glutathione S-transferase. The findings may help researchers plan future cancer studies.

Ethacrynic acid is an approved prescription medicine used to treat fluid buildup. Its use in this study to change these blood markers in healthy adults is experimental.

Up to 40 healthy adults will participate. The first group will receive a 25 mg oral dose at each of two visits approximately one week apart. If results meet the study criteria, a second group will receive 12.5 mg at each visit.

Participants will provide blood samples before and approximately 90 minutes after each dose. Study staff will ask about symptoms during the visits and during a final telephone call approximately one week after the second dose. Participation will last approximately two weeks.

Studieoversikt

Status

Har ikke rekruttert ennå

Intervensjon / Behandling

Detaljert beskrivelse

Glutathione (GSH) and glutathione S-transferases (GSTs) contribute to cellular protection against oxidative stress and the detoxification of electrophilic compounds. In cancer cells, increased activity of these systems may contribute to resistance to anticancer therapies. Ethacrynic acid, an approved loop diuretic, can inhibit GST activity and react with GSH to form conjugates, potentially reducing cellular GSH availability. Whether low oral doses produce measurable pharmacodynamic effects in healthy adults remains uncertain.

TRACer will investigate these biological effects in healthy volunteers to reduce confounding from malignancy, prior cancer treatment, organ dysfunction, and concurrent prescription medications. The study uses paired measurements before and after drug administration, allowing each participant to serve as their own control. Repeating administration approximately one week later will help characterize the consistency of the pharmacodynamic response. Comparison of pre-dose measurements across visits will also provide information about whether changes persist between administrations.

The sequential cohort design evaluates the higher dose first. Enrollment into the lower-dose cohort will occur only if the initial cohort meets the protocol-specified criterion for biological activity. This approach is intended to determine whether target engagement can be demonstrated at doses below those commonly used to produce diuresis.

Peripheral blood mononuclear cells provide accessible material for assessing GST activity. Measurements of total GSH in plasma and erythrocytes provide complementary information about glutathione pools in different blood compartments. Coded specimens will undergo research laboratory analysis at the University of Vermont. These assays will not guide clinical care, and individual research results will not be returned to participants.

The study is intended to inform the design of subsequent investigations of ethacrynic acid as a potential adjunct to cancer therapy. It does not evaluate antitumor activity, and no direct clinical benefit to participants is anticipated.

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Tidlig fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Healthy volunteer without acute or chronic illness.
  • Age 18 years or older.
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • Ongoing use of any prescription medication.
  • Known hypersensitivity to ethacrynic acid.
  • Known renal or hepatic impairment.
  • Current pregnancy or breastfeeding.
  • Current tinnitus, hearing impairment, or other significant hearing disorder.
  • Baseline systolic blood pressure of 100 mm Hg or less.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Ethacrynic Acid 25 mg

Approximately 20 participants will receive ethacrynic acid 25 mg orally at each of two dosing visits separated by one week ±1 day.

Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.

Andre navn:
  • Edecrin
Eksperimentell: Ethacrynic Acid 12.5 mg

If the first cohort meets the protocol-specified biological activity criterion, approximately 20 additional participants will receive ethacrynic acid 12.5 mg orally at each of two dosing visits separated by one week ±1 day.

Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.

Andre navn:
  • Edecrin

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Peripheral Blood Mononuclear Cell GST Activity
Tidsramme: Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later

Change in glutathione S-transferase activity from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Plasma Total Glutathione
Tidsramme: Before dosing and 90 ±15 minutes after dosing at both dosing visits

Change in plasma total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

Before dosing and 90 ±15 minutes after dosing at both dosing visits
Change in Erythrocyte Total Glutathione
Tidsramme: Before dosing and 90 ±15 minutes after dosing at both dosing visits

Change in erythrocyte total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

Before dosing and 90 ±15 minutes after dosing at both dosing visits
Number of Participants With Adverse Events
Tidsramme: From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks

Number of participants experiencing adverse events, summarized by event type, severity, and relatedness. Severity will be graded using the protocol's CTCAE criteria.

From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2029

Primær fullføring (Antatt)

1. januar 2029

Studiet fullført (Antatt)

1. januar 2029

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere